Skip to content

Network of Cancer Research

Reliable, unbiased and up to date information in cancer research

Network of Cancer Research

Reliable, unbiased and up to date information in cancer research

  • Home
  • About
    • Home
    • Gastric Cancer
Gastric Cancer Obesity

JNJ-38877605 is an Orally Active c-Met Inhibitor for Solid Tumour Research

Louis Gilman September 28, 2023

c-Met is a receptor tyrosine kinase involved in embryogenesis, wound healing, and tissue regeneration. Abnormal activation of the MET signaling pathway promotes the growth, survival, migration and invasion of tumor…

Gastric Cancer

LC-MB12 is a FGFR2 PROTAC Degrader for Gastric Cancer Research

Louis Gilman September 14, 2023

Fibroblast growth factor receptor 2 (FGFR2) also known as CD332 (cluster of differentiation 332) is a protein that in humans is encoded by the FGFR2 gene residing on chromosome 10.…

Cancer Esophageal Squamous Cell Carcinoma Gastric Cancer Non-Small Cell Lung Cancer

Afatinib is an Orally Active EGFR/HER2 Dual Inhibitor for Cancer Research

Louis Gilman August 17, 2023

The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). These structurally related receptors…

Cancer Gastric Cancer

MY-943 is a potent Tubulin Polymerization/LSD1 inhibitor that can be used for Gastric Cancer Research

Louis Gilman June 21, 2023

MY-943 is a potent tubulin polymerization and LSD1 inhibitor with anticancer activity. Tubulin in molecular biology can refer either to the tubulin protein superfamily of globular proteins, or one of…

Gastric Cancer

W1131 is a Potent STAT3 Inhibitor for Gastric Cancer Research

Louis Gilman May 5, 2023

STAT3 is a key oncogene whose overactivation leads to cancer. As a transcription factor, it exhibits dual functions of signal transduction and transcriptional activation. Gastric cancer is a malignant tumor usually inhibited…

Cancer Gastric Cancer NSCLC

D6808 is a Highly Selective c‑Met Inhibitor used for NSCLC and Gastric Cancer Research

Louis Gilman December 27, 2022

c-Met is a unique subfamily member of receptor tyrosine kinase (RTK) behaving as the receptor of hepatocyte growth factor (HGF)/scatter factor (SF). The HGF/c-Met signaling pathway plays important roles in…

Cancer Colon Cancer Gastric Cancer

Tivantinib is a Selective c-Met Tyrosine Kinase Inhibitor

Louis Gilman April 30, 2022

c-Met (hepatocyte growth factor receptor, HGFR) is a type of receptor tyrosine kinase which belongs to the MET family.  c-Met exsists in the surfaces of various epithelial cells. Hepatocyte growth…

Gastric Cancer Leukemia

ABT-737 is a Selective and BH3 Mimetic Bcl-2, Bcl-xL and Bcl-w Inhibitor

Louis Gilman December 28, 2021

Bcl-2 protein family is a key regulator of apoptosis and a marker of B-cell lymphoma. Importantly, apoptosis is an important physiological process of selective cell clearance, involving a variety of…

Gastric Cancer

Crizotinib is an Orally Active, ATP-Competitive ALK and c-Met inhibitor

Louis Gilman November 13, 2021

In this article, we will introduce an orally bioavailable, ATP-competitive ALK and c-Met inhibitor, Crizotinib. The IC50 values for ALK and c-Met kinases are 20 and 8 nM, respectively. Additionally, in cell-based assays, Crizotinib…

Gastric Cancer

Pelcitoclax (APG-1252) is a Bcl-2/Bcl-xl Inhibitor with Antineoplastic and Pro-Apoptotic Effects

Louis Gilman July 28, 2021

Bcl-2 (B-cell lymphoma 2) is a family of evolutionarily related proteins. These proteins govern mitochondrial outer membrane permeabilization (MOMP) and can be either pro-apoptotic (Bax, Bad, Bak and Bok among…

Posts navigation

1 2

Next Page »

Recent Posts

  • BI 7446 is a STING Agonist for Immuno-oncology Research
  • JNJ-38877605 is an Orally Active c-Met Inhibitor for Solid Tumour Research
  • OATD-02 is an Orally Active Arginase 1/2 Inhibitor for Melanoma Research
  • INCB086550 is an Orally Active PD-L1 Inhibitor for Multiple Cancers Research
  • Panobinostat is a HDAC Inhibitor for Multiple Myeloma Research

Archives

  • September 2023
  • August 2023
  • July 2023
  • June 2023
  • May 2023
  • April 2023
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • June 2020
  • May 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019

Categories

  • Abdominal Aortic Aneurysm
  • Acute Leukemia
  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Adenoid Cystic Carcinoma
  • Adenomyosis
  • Adrenocortical carcinoma
  • Adult T-cell leukemia/lymphoma
  • Anti-angiogenic
  • anti-inflammatory
  • antioxidant
  • autoimmune disease
  • B-cell malignancies
  • Bladder Cancer
  • Bone Cancer
  • Brain Cancer
  • Breast Cancer
  • Cancer
  • Cancer Metastases
  • Castration Resistant Prostate Cancer
  • ccRCC
  • Cervical Cancer
  • Cervix Cancer
  • Chemotherapy
  • Chemotherapy Side Effects
  • Cholangiocarcinoma
  • Chronic Lymphocytic Leukemia
  • Chronic Myeloid Leukemia
  • Colon Adenocarcinoma
  • Colon Cancer
  • Colorectal Cancer
  • Colorectal Cancer
  • Endometrial Adenocarcinoma
  • Endometrial Cancer
  • ER+ Breast Cancer
  • Esophageal Squamous Cell Carcinoma
  • Esophagus Cancer
  • Ewing's Sarcoma
  • Fibrosarcoma
  • Follicular Lymphoma
  • Gastric Adenocarcinoma
  • Gastric Cancer
  • Gastrointestinal Stromal Tumor
  • Glioblastoma
  • Glioblastoma Multiforme
  • Gliocytoma
  • Glioma
  • Head & Neck Cancer
  • Head and Neck Cancer
  • Hematologic Neoplasms
  • Hematological Malignancies
  • Hepatocellular carcinoma
  • HER2+ Breast Cancer
  • Hodgkin Lymphoma
  • HPV
  • HSV-1
  • Idiopathic Pulmonary Fibrosis
  • Kaposi's Sarcoma
  • Kidney Cancer
  • Large B Cell Lymphoma
  • Large B-cell Lymphoma
  • Large Cell Lung Cancer
  • Leukemia
  • Liver Cancer
  • Lung Adenocarcinoma
  • Lung Cancer
  • Lymphoma
  • Malaria
  • Mantle Cell Lymphoma
  • Medullary Thyroid Carcinoma
  • Medulloblastoma
  • Medulloblastomas
  • Megakaryoblastic Leukemia
  • Melanoma
  • Mesothelioma
  • Metabolism
  • Metabolism-related diseases
  • Metastatic Castration-resistant Prostate Cancer
  • Multiple Myeloma
  • Myelodysplastic Syndrome
  • Myelodysplastic Syndrome
  • Myeloma
  • Nasopharyngeal Carcinoma
  • Neoplasms
  • Neuroblastoma
  • Neuroendocrine Tumors
  • Neuropathy
  • Non-Hodgkin Lymphoma
  • Non-Small Cell Lung Cancer
  • NSCLC
  • NUT midline carcinoma
  • Obesity
  • Oesophageal Cancer
  • Oral Carcinoma
  • Osteosarcoma
  • Ovary Cancer
  • Pancreas Cancer
  • Pancreatic cancer
  • Pancreatic Ductal Adenocarcinoma
  • Ph+ ALL
  • Philadelphia-positive Leukemias
  • Plasmacytoma
  • Prostate Cancer
  • PROTAC
  • Renal Carcinoma
  • Sarcoma
  • Skin Cancer
  • Small Cell Lung Cancer
  • Soft Tissue Tumor
  • Solid Tumors
  • Squamous Carcinoma
  • T Acute Lymphoblastic Leukemia
  • T-cell Lymphoma
  • Thyroid Cancer
  • Triple-Negative Breast Cancer
  • uncategorized
  • Uterine Serous Carcinoma

You Missed

Breast Cancer

BI 7446 is a STING Agonist for Immuno-oncology Research

Gastric Cancer Obesity

JNJ-38877605 is an Orally Active c-Met Inhibitor for Solid Tumour Research

Multiple Myeloma Myeloma

OATD-02 is an Orally Active Arginase 1/2 Inhibitor for Melanoma Research

autoimmune disease

INCB086550 is an Orally Active PD-L1 Inhibitor for Multiple Cancers Research

Network of Cancer Research

Reliable, unbiased and up to date information in cancer research

Copyright © All rights reserved | Blogus by Themeansar.